Sign In
Buy HURN
Huron Consulting Group Earnings Calls
| Release date | Oct 28, 2025 |
| EPS estimate | $1.88 |
| EPS actual | $2.10 |
| EPS Surprise | 11.70% |
| Revenue estimate | 418.127M |
| Revenue actual | 441.284M |
| Revenue Surprise | 5.54% |
| Release date | Jul 31, 2025 |
| EPS estimate | $1.79 |
| EPS actual | $1.89 |
| EPS Surprise | 5.59% |
| Revenue estimate | 411.854M |
| Revenue actual | 402.505M |
| Revenue Surprise | -2.27% |
| Release date | Apr 29, 2025 |
| EPS estimate | $1.16 |
| EPS actual | $1.68 |
| EPS Surprise | 44.83% |
| Revenue estimate | 389.273M |
| Revenue actual | 404.141M |
| Revenue Surprise | 3.82% |
| Release date | Feb 25, 2025 |
| EPS estimate | $1.52 |
| EPS actual | $1.90 |
| EPS Surprise | 25.00% |
| Revenue estimate | 380.62M |
| Revenue actual | 399.314M |
| Revenue Surprise | 4.91% |
Last 4 Quarters for Huron Consulting Group
Below you can see how HURN performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 25, 2025 |
| Price on release | $125.33 |
| EPS estimate | $1.52 |
| EPS actual | $1.90 |
| EPS surprise | 25.00% |
| Date | Price |
|---|---|
| Feb 19, 2025 | $131.22 |
| Feb 20, 2025 | $128.88 |
| Feb 21, 2025 | $123.74 |
| Feb 24, 2025 | $125.30 |
| Feb 25, 2025 | $125.33 |
| Feb 26, 2025 | $148.18 |
| Feb 27, 2025 | $149.58 |
| Feb 28, 2025 | $152.46 |
| Mar 03, 2025 | $148.42 |
| 4 days before | -4.49% |
| 4 days after | 18.42% |
| On release day | 18.23% |
| Change in period | 13.11% |
| Release date | Apr 29, 2025 |
| Price on release | $135.94 |
| EPS estimate | $1.16 |
| EPS actual | $1.68 |
| EPS surprise | 44.83% |
| Date | Price |
|---|---|
| Apr 23, 2025 | $137.21 |
| Apr 24, 2025 | $134.48 |
| Apr 25, 2025 | $134.14 |
| Apr 28, 2025 | $135.26 |
| Apr 29, 2025 | $135.94 |
| Apr 30, 2025 | $134.79 |
| May 01, 2025 | $140.92 |
| May 02, 2025 | $147.36 |
| May 05, 2025 | $148.31 |
| 4 days before | -0.93% |
| 4 days after | 9.10% |
| On release day | -0.85% |
| Change in period | 8.09% |
| Release date | Jul 31, 2025 |
| Price on release | $132.08 |
| EPS estimate | $1.79 |
| EPS actual | $1.89 |
| EPS surprise | 5.59% |
| Date | Price |
|---|---|
| Jul 25, 2025 | $133.49 |
| Jul 28, 2025 | $133.89 |
| Jul 29, 2025 | $134.14 |
| Jul 30, 2025 | $131.93 |
| Jul 31, 2025 | $132.08 |
| Aug 01, 2025 | $121.98 |
| Aug 04, 2025 | $126.55 |
| Aug 05, 2025 | $127.89 |
| Aug 06, 2025 | $128.91 |
| 4 days before | -1.06% |
| 4 days after | -2.40% |
| On release day | -7.65% |
| Change in period | -3.43% |
| Release date | Oct 28, 2025 |
| Price on release | $152.48 |
| EPS estimate | $1.88 |
| EPS actual | $2.10 |
| EPS surprise | 11.70% |
| Date | Price |
|---|---|
| Oct 22, 2025 | $152.45 |
| Oct 23, 2025 | $153.14 |
| Oct 24, 2025 | $153.07 |
| Oct 27, 2025 | $153.64 |
| Oct 28, 2025 | $152.48 |
| Oct 29, 2025 | $169.61 |
| Oct 30, 2025 | $165.40 |
| Oct 31, 2025 | $164.44 |
| Nov 03, 2025 | $165.70 |
| 4 days before | 0.0197% |
| 4 days after | 8.67% |
| On release day | 11.23% |
| Change in period | 8.69% |
Huron Consulting Group Earnings Call Transcript Summary of Q3 2025
Huron delivered a strong Q3 2025 with record revenues before reimbursable (RBR) of $432.4M, up 16.8% year-over-year and 10.2% organic growth. All three segments hit record RBRs: Healthcare $219.5M (+19.9%), Education $129.4M (+6.9%), and Commercial $83.4M (+26.6%) (Commercial growth partly acquisition-driven). Adjusted EBITDA rose to $67.4M (15.6% of RBR) and adjusted EPS was $2.10 (25% increase vs. Q3 2024). Healthcare showed particularly strong organic demand (performance improvement, revenue cycle managed services, financial advisory), with management calling it the strongest market they have seen. The company is expanding AI and automation across offerings. Management narrowed full-year RBR guidance to $1.65B–$1.67B, affirmed adjusted EBITDA guidance of 14.0%–14.5% of RBR, and raised adjusted non‑GAAP EPS guidance to $7.50–$7.70. Cash flow from operations was $93.8M in the quarter, free cash flow $85.3M; net debt was $587.1M and leverage was ~2.3x adjusted EBITDA (expecting ~2.0x at year-end). The company completed acquisitions (Eclipse Insights, Treliant, Wilson Perumal) and repurchased $18.6M of stock in Q3 ($152.5M YTD), with $112.6M remaining buyback authorization. Management expects continued strong pipeline, improving sales conversion in several areas (notably healthcare and parts of commercial), and margin expansion over time though Commercial margins are currently depressed by acquisition-related mix and ramp costs.
